• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Marker Therapeutics Inc.

    4/24/25 4:43:44 PM ET
    $MRKR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRKR alert in real time by email
    DEFA14A 1 tm252466d3_defa14a.htm DEFA14A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.)

     

    Filed by the Registrant x  
       
    Filed by a party other than the Registrant ¨  

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
       
    ¨ Confidential, for use of the Commission Only (as permitted by Rule 14a-6(e)(2))
       
    ¨ Definitive Proxy Statement
       
    x Definitive Additional Materials
       
    ¨ Soliciting Material Pursuant to §240.14a-12

     

    Marker Therapeutics, Inc.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    x No Fee Required
       
    ¨ Fee paid previously with preliminary materials.
       
    ¨ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     

     

     

     

    GRAPHIC

    Get informed before you vote *If you choose to vote these shares in person at the meeting, you must request a “legal proxy.” To do so, please follow the instructions at www.ProxyVote.com or request a paper copy of the materials, which will contain the appropriate instructions. Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number Your Vote Counts! FLASHID-JOB# For complete information and to vote, visit www.ProxyVote.com Control # Ricky Campana P.O. Box 123456 Suite 500 51 Mercedes Way Edgewood, NY 11717 148,294 322,224 1 OF 2 30# Hextone, Inc. P.O. Box 9142 Farmingdale, NY 11735 XXXX XXXX XXXX XXXX MARKER THERAPEUTICS, INC. 2025 Annual Meeting Vote by June 05, 2025 11:59 PM ET You invested in MARKER THERAPEUTICS, INC. and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 06, 2025. View the Form 10-K, Proxy Statement online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 25, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote in Person at the Meeting* June 06, 2025 10:00 AM EDT Annual Meeting to be held virtually To attend, you must register as a Beneficial Holder at the below URL: https://web.viewproxy.com/markertherapeutics/2025AM

    GRAPHIC

    Voting Items Board Recommends THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com FLASHID-JOB# Control # XXXX XXXX XXXX XXXX 1.00000 322,224 148,294 Under New York Stock Exchange rules, brokers may vote “routine” matters at their discretion if your voting instructions are not communicated to us at least 10 days before the meeting. We will nevertheless follow your instructions, even if the broker’s discretionary vote has already been given, provided your instructions are received prior to the meeting date. MARKER THERAPEUTICS, INC. 2025 Annual Meeting Vote by June 05, 2025 11:59 PM ET 1. Election of Directors Nominees: 01 David Eansor 03 Juan Vera 02 Steven Elms 04 Katharine Knobil For 2 To approve, on an advisory basis, the compensation of the Company's named executive officers. For 3 Ratification of the selection by the Audit Committee of the Board of Directors of Marcum LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

    Get the next $MRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRKR

    DatePrice TargetRatingAnalyst
    3/5/2025$8.00Buy
    Canaccord Genuity
    2/17/2022$3.00 → $1.00Buy → Neutral
    Roth Capital
    More analyst ratings

    $MRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Marker Therapeutics Inc. (Amendment)

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      5/17/24 6:25:14 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      3/26/21 10:38:04 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Marker Therapeutics, Inc.

      SC 13D/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      3/15/21 4:45:13 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Elms Steve

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:20:34 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Knobil Katharine

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:19:38 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Eansor Norman David

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      2/14/25 5:18:35 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

      HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

      5/19/25 8:00:12 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference

      HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity's Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors. Panel Participation Details: EventCG Horizons in Onc

      4/1/25 8:00:14 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

      Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses Secured over $13 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and the National Institute of Health (NIH) Small Business Innovation Research (SBIR) to support pancreatic and lymphoma clinical programs Approval from United States Adopted Name (USAN) council and International Nonproprietary Names (INN) expert committee for "neldaleucel" as nonproprietary name for MT-601 Strategic financing to support cli

      3/31/25 8:45:00 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    SEC Filings

    See more
    • Marker Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Marker Therapeutics, Inc. (0001094038) (Filer)

      5/20/25 8:32:01 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Marker Therapeutics Inc.

      10-Q - Marker Therapeutics, Inc. (0001094038) (Filer)

      5/15/25 5:00:50 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Marker Therapeutics Inc.

      SCHEDULE 13G/A - Marker Therapeutics, Inc. (0001094038) (Subject)

      5/15/25 4:13:40 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Marker International with a new price target

      Canaccord Genuity initiated coverage of Marker International with a rating of Buy and set a new price target of $8.00

      3/5/25 7:37:58 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics downgraded by Roth Capital with a new price target

      Roth Capital downgraded Marker Therapeutics from Buy to Neutral and set a new price target of $1.00 from $3.00 previously

      2/17/22 6:14:24 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Marker Therapeutics with a new price target

      Piper Sandler initiated coverage of Marker Therapeutics with a rating of Overweight and set a new price target of $6.00

      3/25/21 6:18:22 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Elms Steve bought $35,472 worth of shares (11,085 units at $3.20) (SEC Form 4)

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      12/26/24 4:01:17 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner New Enterprise Associates 16, L.P. bought $1,773,600 worth of shares (554,250 units at $3.20) (SEC Form 4)

      4 - Marker Therapeutics, Inc. (0001094038) (Issuer)

      12/23/24 4:40:48 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRKR
    Leadership Updates

    Live Leadership Updates

    See more

    $MRKR
    Financials

    Live finance-specific insights

    See more
    • Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

      HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (NASDAQ:MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by Demy-Colton in collaboration with the WBB Research Institute titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?". The virtual event is scheduled to take place on May 28, 2025, at 11:00 a.m. EDT. This one-hour virtual event will feature insights from leading voices in the cell therapy space, f

      5/19/25 8:00:12 AM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors

      CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo

      8/28/24 8:00:00 AM ET
      $KRRO
      $MRKR
      $PLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results

      Lead program in patients with lymphoma demonstrated preliminary safety and efficacy results with sustained complete response in first study participant treated with MT-601 (Neldaleucel) following CAR T relapse Secured non-dilutive funding of $2 million from National Institute of Health (NIH) to support clinical program for treatment of patients with Acute Myeloid Leukemia (AML) Received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for multiTAA-specific T cell product candidate MT-401 (Zedenoleucel) for the treatment of patients with AML Implemented leadership transition resulting in appointments of Juan Vera, M.D. as President and Chief Executive Officer and Monic St

      3/25/24 5:45:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Announces Clinical Program Updates and Pipeline Expansion

      Results from safety lead-in stage of Marker's Phase 2 AML trial demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) in one MRD+ patient and induced epitope spreading New T cell manufacturing process for MT-401 and other product candidates designed to improve potency, increase antigen specificity and diversity and significantly reduce manufacturing time Company announces clinical updates, including plans to file additional INDs by year end, with clinical trials in solid tumors and blood cancers to be initiated in 2023 Company to host conference call and webcast at 5:00 p.m. EST today HOUSTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, In

      2/16/22 4:30:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics to Host Clinical Program Update Conference Call and Webcast on Wednesday, February 16, 2022

      HOUSTON, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, February 16, 2022 at 5:00 p.m. EST to provide an update on the Company's clinical programs, manufacturing processes and pipeline. The webcast will be accessible in the Investors section of the Company's website at www.markertherapeutics.com. Individuals can participate in the conference call by dialing 877-869-3847 (domestic) or 201-68

      2/8/22 4:05:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Marker Therapeutics Reports Third Quarter 2021 Operating and Financial Results

      HOUSTON, Nov. 10, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today provided a corporate update and reported financial results for the third quarter ended September 30, 2021.   "This quarter, we continued our momentum in advancing Marker's Phase 2 trial of MT-401, Marker's lead MultiTAA-specific T cell therapy, for the treatment of post-transplant acute myeloid leu

      11/10/21 4:05:00 PM ET
      $MRKR
      Biotechnology: Pharmaceutical Preparations
      Health Care